Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Twin SUBLIVAC Grasses Clinical Efficacy Study
2005-005175-16Phase 3Completed
- Sponsor
- HAL Allergy Group
- Start
- Apr 2006
- Modality
- Subcutaneous Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics, Sublingual Immunotherapy → Allergy Immunotherapy → Therapeutic Vaccines → Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in allergic rhinoconjunctivitis (ARC), asthma and allergic rhinitis (AR) comparing SUBLIVAC Grasses with Placebo / control (2 arms). Primary endpoint: Mean clinical index score during pollen season. Started Apr 2006; status: completed.
02
Drugs
Sublivac Grasses
03
Conditions
allergic rhinoconjunctivitis (ARC)asthmaallergic rhinitis (AR)
Beyond the preview
Go deeper on 2005-005175-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-005175-16.